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Abstract
Exposure of human erythrocytes to elevated intracellular calcium causes fragments of the
cell membrane to be shed as microvesicles. This study tested the hypothesis that
microvesicle release depends on microscopic membrane physical properties such as lipid
order, fluidity, and composition. Membrane properties were manipulated by varying the
experimental temperature, membrane cholesterol content, and the activity of the trans-
membrane phospholipid transporter, scramblase. Microvesicle release was enhanced by
increasing the experimental temperature. Reduction in membrane cholesterol content by
treatment with methyl--cyclodextrin also facilitated vesicle shedding. Inhibition of
scramblase with R5421 impaired vesicle release. These data were interpreted in the
context of membrane characteristics assessed previously by fluorescence spectroscopy
with environment-sensitive probes such as laurdan, diphenylhexatriene, and merocyanine
540. The observations supported the following conclusions: 1) calcium-induced
microvesicle shedding in erythrocytes relates more to membrane properties detected by
diphenylhexatriene than by the other probes; 2) loss of trans-membrane phospholipid
asymmetry is required for microvesicle release.
PACS Codes: 87.16.dj, 87.16.dt
Introduction
We have recently reported the use of fluorescence spectroscopy to generate a pseudo phase map
of physical properties of erythrocyte membranes as a function of temperature and membrane
cholesterol content [1]. These experiments used three fluorescent probes that differ slightly in the
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properties they detect based on companion experiments with artificial membranes of defined
composition. The result was the equivalent of a phase diagram mapping properties such as lipid
order, spacing, and fluidity for intact human erythrocytes. These studies were complemented by
a preliminary effort using the enzyme phospholipase A2 to determine whether there was any
functional significance to the various regions of membrane behaviors observed by the probes [2].
The success of that initial attempt has prompted us to pursue additional erythrocyte membrane
processes to assess their relationship to membrane properties. We report here our investigations
of the relationship between microvesicle release and the pseudo phase map.
Microvesicle shedding is stimulated in human erythrocytes by sustained elevation of intracel-
lular calcium [3]. Other events associated with calcium influx in erythrocytes include: opening of
calcium-dependent potassium channels, leading to potassium ion efflux [4,5]; activation of cal-
cium-dependent proteases, including calpain [3]; activation of the phospholipid transporter
scramblase, leading to exposure of phosphatidylserine in the outer leaflet of the bilayer [6,7];
cytoskeletal alterations [8-12], a change in erythrocyte morphology from the normal discoid
shape to a spherical shape; and an increase in order of membrane lipids as detected by the fluo-
rescent probe laurdan [3,13].
Apparently, several of these calcium-dependent events are involved in the mechanism of
microvesicle production and shedding. For example, convincing evidence argues that activation
of both calpain and the calcium-dependent potassium channel is critical for vesicle release
[3,4,14,15]. Cytoskeletal and membrane proteins such as synexin, a protein involved in bilayer
fusion, are also likely to be involved [16]. Studies in platelets have suggested that tyrosine
dephosphorylation may regulate proteins involved in the process [17,18]. Although several lines
of evidence suggest that translocation of phosphatidylserine is also required, other data have
implied the opposite conclusion [15,19-21]. To our knowledge, a potential role for membrane
biophysics in microvesicle release has not yet been explored. Nevertheless, the distinct character-
istics of microvesicle membranes, such as enrichment with lipid rafts, support this hypothesis
[16,22].
To investigate the contributions of membrane composition and biophysical properties to cal-
cium-regulated microvesicle release, we altered membrane cholesterol content, temperature, and
the activity of scramblase in human erythrocytes treated with ionomycin, a calcium ionophore.
We compared the results quantitatively to prior measurements of membrane properties in
pseudo phase maps constructed as a function of temperature and cholesterol content [1]. Phos-
phatidylserine exposure was manipulated using the pharmacological agent R5421, a specific
inhibitor of scramblase [23].PMC Biophysics 2009, 2:7 http://www.physmathcentral.com/1757-5036/2/7
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Materials and methods
Materials
The intracellular calcium indicator indo-1 (acetoxymethyl ester form), laurdan, and the Amplex
®
Red cholesterol assay kit were purchased from Invitrogen (Carlsbad, CA). Ionomycin was
obtained from Calbiochem (La Jolla, CA) and methyl--cyclodextrin (MBCD) and quinine were
purchased from Sigma-Aldrich (St. Louis, MO). R5421 was a generous gift from Jeffrey T. Billhe-
imer at Dupont Merck Research Laboratory (Wilmington, DE). All other reagents were obtained
from standard sources. Ionomycin, R5421, laurdan, and indo-1 were dissolved in dimethylsul-
foxide (DMSO). Quinine was dissolved in ethanol. Stocks of all other reagents were prepared as
aqueous solutions.
Erythrocytes were obtained from blood samples obtained during physical exams at the
Brigham Young University Student Health Center. The samples were fresh or stored up to 2 days
at 4°C in EDTA vacutainers from which patient identification was removed. Control experiments
comparing fresh blood with stored samples demonstrated that these storage conditions did not
influence the results [3].
Erythrocytes were isolated and washed by centrifugation as described previously [3], resus-
pended to the original hematocrit (hct) in a balanced salt buffer (NaCl = 134 mM, KCl = 6.2 mM,
CaCl2 = 1.6 mM, MgCl2 = 1.2 mM, Hepes = 18.0 mM, glucose = 13.6 mM, pH 7.4, 37°C). To ver-
ify that results were due to transport of calcium (and not magnesium) by ionomycin, experi-
ments were repeated in a variant of this medium in which the typical calcium and magnesium
salts were replaced with different concentrations of CaCl2. The minimum amount of CaCl2 suffi-
cient to produce a full response was 0.6 mM. Under that condition, the results were indistin-
guishable regardless of which medium was used; hence, the data obtained with both media were
pooled. The ionomycin concentration for all experiments was 300 nM.
Extraction of membrane cholesterol
Washed erythrocytes were suspended in buffer at 0.15% hct and incubated in the presence or
absence of varying concentrations of MBCD (0, 0.1, 0.3, 0.6, or 1.0 mM) for 30 min at 37°C.
Cells were washed and re-suspended in fresh medium for experiments. The amount of choles-
terol extracted from the cells was quantified using the Amplex
® Red cholesterol assay kit (Invitro-
gen, Carlsbad, CA) on methanol/chloroform extracts of samples as described [1].
Fluorescence spectroscopy and light scattering
Steady-state fluorescence (indo-1) and sample light scatter intensity and noise were monitored
using photon-counting spectrofluorometers (Fluoromax-1 and Fluoromax-3 from Jobin Yvon,
Edison, NJ, and PC1 from ISS, Champaign, IL). All three instruments maintain sample homoge-
neity by continuous gentle stirring with a magnetic stir bar. Control experiments (not shown)
showed that stir bar speed did not influence light scatter noise. Sample temperature was control-PMC Biophysics 2009, 2:7 http://www.physmathcentral.com/1757-5036/2/7
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led and maintained using circulating water baths and equilibrated for at least 5 min to achieve
temperature stability. Simultaneous assessment of fluorescence intensity at multiple excitation
and emission wavelengths was obtained by rapid sluing of monochromator mirrors using con-
trol software provided with the instrument. Band pass was set at 4 nm for both monochromators
in each case.
Intracellular calcium concentrations at 25°C, 37°C and 45°C were assessed using indo-1 as
explained previously [24]. Erythrocyte samples were prepared as described above and further
diluted to 1% hct. The acetoxymethyl ester of indo-1 (final concentration = 2.5 M) was added,
and the samples were incubated 60 min at 37°C in a shaking water bath. Cells were washed,
resuspended in fresh buffer, placed in cuvette (0.075% hct) and incubated at the indicated tem-
perature in the fluorometer sample chamber. Fluorescence was continuously monitored (excita-
tion = 350 nm, emission = 405 and 480 nm). A baseline was established for 3 min, followed by
the addition of ionomycin, and then continued data acquisition for several min.
Phosphatidylserine exposure on the outer leaflet of the cell membrane was assayed by meas-
uring the fluorescence intensity of dansylarginine-N-(3-ethyl-1,5-pentanediyl)amide (3 M
final, excitation = 335 nm, emission = 545 nm) as described [3,25]. This method detects phos-
phatidylserine by monitoring the rate at which it converts prothrombin to thrombin. A positive
control was obtained by the addition of thrombin (2.7 M).
For light scatter experiments, cell suspensions (0.075% hct) were incubated at the indicated
temperature as for fluorescence. Monochromator settings were 500 nm for excitation and 510
nm for emission. As with indo-1 fluorescence measurements, light scatter data were gathered
before and continued after ionomycin addition.
Results
As shown in Figures 1A and 1C, the addition of ionomycin to human erythrocytes in the presence
of calcium caused an increase in the intensity of light scattered by the sample concurrent with a
decrease in the signal noise at 37 and 43°C. At 22°C, these effects were reduced or absent. Pre-
vious studies have demonstrated that the elevated scattering intensity results from an increase in
sample turbidity due to microvesicle shedding [3]. Accordingly, when an inhibitor of microvesi-
cle release was included in the experiment (quinine, see Ref. [5]), the rise in light scatter intensity
was greatly reduced (Figure 1B). Instead, the intensity of scattered light decreased because of the
calcium-stimulated transition in erythrocyte shape from discocyte to the smaller rounded form
termed "spherocyte" [3]. In some cases, the release of microvesicles appeared to be slower than
the shape transition leading to an initial drop in light scatter intensity followed by a latent rise
(Figure 1C). Previous studies have demonstrated that the reduction in scatter noise also reflects
the transition of erythrocyte shape [3,26].PMC Biophysics 2009, 2:7 http://www.physmathcentral.com/1757-5036/2/7
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The light scatter data were quantified as illustrated in Figure 1C. First, the time profile was fit
by nonlinear regression to an arbitrary function (white curve):
Effect of ionomycin on light scattered by erythrocytes suspensions Figure 1
Effect of ionomycin on light scattered by erythrocytes suspensions. Panel A: Erythrocytes were treated 
with ionomycin (added at the dashed line) at 22°C or 37°C. The data are normalized to the average intensity prior 
to addition of ionomycin. Panel B: The 37°C experiment of Panel A was repeated in the presence of 1 mM quinine. 
Panel C: The experiment of Panel A was repeated at 43°C. Ionomycin was added at time zero. The dotted lines 
indicate the minimum in intensity (Imin) and the time 240 s later at which I240 is evaluated. The other parameters rel-
evant to Eq. 2 are indicated in the figure. The white curve was obtained by nonlinear regression of the data using Eq. 
1.
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where I(t) is the light scatter intensity as a function of time, I0 is the initial intensity prior to
addition of ionomycin, and A, B, C, D, and E are arbitrary coefficients. The amount of microves-
icle release (M) was estimated by calculating the maximum displacement in scatter intensity.
This displacement was standardized to a time frame of 240 s (since vesicle release appears con-
tinuous) and normalized to I0 to account for variations in sample hematocrit and instrument sen-
sitivity. Imin and I240 are defined as shown in Figure 1C; Imin is the minimum intensity calculated
from the regression to Eq. 1 and I240 is the intensity 240 s after the time corresponding to Imin.
The effect of temperature on microvesicle release (Eq. 2) is summarized in Figure 2. The
change in intensity (M) was minimal and equal to a value of approximately zero at the lowest
temperatures. High temperature sensitivity was observed in the range of 30 to 45°C. The inflec-
tion point for the effect of temperature occurred at 38.5 ± 3.5°C (midpoint ± 95% margin of
error).
In order to establish that the observed temperature dependence was not due to differences in
the ability of ionomycin to transport ions from the extracellular environment, we used the fluo-
rescent probe indo-1 to report relative internal calcium ion concentration at 25°C, 37°C, and
Effect of temperature on light scatter intensity Figure 2
Effect of temperature on light scatter intensity. The experiments shown in Figure 1A were repeated at mul-
tiple temperatures between 20 and 50°C. Experiments were analyzed for light scatter intensity displacement (M) 
(an index of microvesicle release) using Eqs. 1 and 2. Data points were grouped from several similar temperatures 
and expressed as mean ± SEM in both dimensions (n = 8–15). The data were fit by nonlinear regression using an 
arbitrary function. The 95% confidence interval of the inflection point was 35.0–42.0.
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45°C. There was no statistical difference in the level of calcium achieved after 240 s (the time
range covered by the experiments of this study, Figure 3). This result was further validated by
examining longer time courses (600–3000 s, data not shown).
To assess the effect of cholesterol on calcium-stimulated microvesicle release, we repeated the
experiments of Figure 1 over a range of temperatures from 24 to 45°C (as in Figure 2) before and
after depletion of membrane cholesterol (Figure 4). Removal of cholesterol by MBCD treatment
resulted in greater differences in light scatter intensity before and after the addition of ionomycin.
Two-way analysis of variance showed that both MBCD treatment and temperature had a signifi-
cant effect on the results (p < 0.0001 for both), and that the interaction between the two was also
significant (p = 0.02, n = 3–4). This interaction between temperature and MBCD concentration
confirmed statistically the visual appearance of the data, suggesting that manifestation of the
effect of cholesterol depletion occurs to a greater extent at the higher temperatures.
By varying both parameters, we were able to calculate a two-dimensional profile of iono-
phore-induced vesicle shedding and illustrate it as a contour plot in Figure 5 (white lines). The
contour plot is shown overlaying pseudo phase maps of membrane properties generated in an
earlier investigation in which cholesterol and temperature were similarly varied [1]. The different
panels in the figure represent properties assessed with merocyanine 540 (Panel A), laurdan
(Panel B), and diphenylhexatriene (Panel C). Although these three probes detect interrelated
physical behaviors, studies with artificial membranes of defined composition have made it clear
Effect of temperature on calcium transport by ionomycin Figure 3
Effect of temperature on calcium transport by ionomycin. Data were obtained using indo-1 to monitor 
internal calcium concentration (see Materials and Methods). Calcium concentration was estimated by calculating 
the ratio of fluorescence emission intensities at 480 to 405 nm. Data were analyzed by one-way analysis of variance 
(p = 0.71, n = 2–3) and are expressed as mean ± SEM.
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that observations with them are not redundant, and that they are differentially sensitive to vari-
ous parameters. For example, merocyanine 540 intensity appears most sensitive to interlipid
spacing in the headgroup region along the plane of the membrane [1,27-29]. In Figure 5A,
increased color brightness denotes greater spacing (increased emission intensity). Laurdan emis-
sion spectral shape detects changes in the amount of water invading the bilayer, which tracks
closely with lipid order [1,29-32]. In Figure 5B, increased brightness reflects increased disorder
(shift of emission spectrum toward longer wavelengths). Diphenylhexatriene anisotropy is also
very sensitive to lipid order since movement of the probe in the membrane is mostly determined
by physical constraints imposed by the phospholipid acyl chains. Nevertheless, it appears to
detect additional lipid movement that laurdan spectra do not sense [1,29,33,34]. For the pur-
poses of this paper, we refer to this additional sensitivity as "fluidity" since it distinguishes solid-
ordered and liquid-ordered phases in artificial membranes [1,29]. In Figure 5C increased bright-
ness corresponds to increased fluidity and disorder (reduced anisotropy). Visual inspection of the
overlaid data suggests that the pattern of microvesicle release as a function of both temperature
and membrane cholesterol content best matches the pattern of diphenylhexatriene fluorescence.
The visual observations in Figures 5A–C were confirmed by correlation analysis (Figures 5D–
F). Diphenylhexatriene anisotropy was the fluorescence parameter showing the highest correla-
Effect of membrane MBCD treatment on the temperature dependence of light scatter intensity Figure 4
Effect of membrane MBCD treatment on the temperature dependence of light scatter intensity. The 
experiments of Figure 2 were repeated in samples from which membrane cholesterol had been depleted by MBCD 
(see Materials and Methods). Based on previous calculations [1], samples contained 46.8% (untreated, open circles), 
40.7% (treated with 0.3 mM MBCD, solid circles), or 19.0% (treated with 1.0 mM MBCD, open triangles) mem-
brane cholesterol. Data were analyzed as in Figure 2 and expressed as mean ± SEM (n = 3–4). The effects of MBCD 
concentration and temperature were both significant by two-way ANOVA (p < 0.0001 in both cases, p = 0.04 for 
interaction). Two additional concentrations of MBCD not shown in the figure (0.1 mM or 44.9% cholesterol and 
0.6 mM or 33.0% cholesterol) were included in the analysis of variance.
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tion with and least systematic deviation from the level of microvesicle release (Figure 5F; r
2 = 0.63
for merocyanine 540, 0.56 for laurdan, and 0.75 for diphenylhexatriene). Multiple regression
yielded similar results. When all three pseudo phase maps were considered simultaneously, only
laurdan and diphenylhexatriene fluorescence were significant predictors of the rate of microves-
icle shedding (p < 0.008 in each case). Nevertheless, diphenylhexatriene explained a greater pro-
portion of the variation in vesicle release rates than laurdan (41% versus 19%). These results
suggest that membrane fluidity is the property upon which the ability of ionomycin to induce
microvesicle release depends most.
Contour plot of microvesicle release superimposed on phase maps of membrane properties observed previously  with the fluorescent probes merocyanine 540, laurdan, and diphenylhexatriene Figure 5
Contour plot of microvesicle release superimposed on phase maps of membrane properties 
observed previously with the fluorescent probes merocyanine 540, laurdan, and diphenylhexatriene. 
The white contour lines represent increments of 0.08 normalized units of light scatter intensity change (same units 
as Figure 4). Contour lines were obtained by a two-step nonlinear regression as described previously [1]. Data 
analogous to those displayed in Figure 4 were first fit to arbitrary functions (e.g. polynomials) with curves for each 
cholesterol concentration and with temperature as the independent variable. The idealized values obtained from 
these regressions were then fit again with cholesterol concentration as the independent variable and separate 
curves for each temperature. The optimized values from the second regression were then used to generate a 3-
dimensional surface with the Z-axis (intensity) oriented perpendicular to the plane of the figure. These contour 
plots were superimposed on phase maps for erythrocytes reported previously [1]. Panel A: Merocyanine 540 fluo-
rescence intensity; increasing brightness indicates increasing intensity (from 0.64 to 0.89 normalized units). Panel B: 
Laurdan fluorescence generalized polarization (GP, see Ref. [1] for details); increasing brightness indicates decreas-
ing GP (from 0.26 to 0.022 GP units). Panel C: Diphenylhexatriene anisotropy; increasing brightness indicates 
decreasing anisotropy (from 0.24 to 0.18 anisotropy units). Panels D-F: The values used to generate the phase maps 
("probe fluorescence") were plotted against the values used to generate the white contour lines ("microvesicle 
release") for merocyanine 540 (D), laurdan (E), and diphenylhexatriene (F). The solid lines represent perfect corre-
lation for reference (not a linear regression).
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The role of phosphatidylserine exposure in calcium-stimulated microvesicle release was stud-
ied using the scramblase inhibitor, R5421. At the concentration used, R5421 reduced the amount
of phosphatidylserine translocated to the outer leaflet of the cell membrane during calcium
influx by more than 50% (see Figure 6A and Ref. [3]). Under such conditions, microvesicle
release also appeared to be significantly inhibited by the drug (Figure 6B).
Discussion
Our purpose was to characterize microvesicle release from ionophore-treated erythrocytes in
terms of microscopic membrane physical properties such as lipid order, fluidity, and composi-
tion. Previous studies had shown that these properties could be manipulated in human erythro-
cytes by altering temperature [13], membrane cholesterol content [1,29], and by using the
scramblase inhibitor R5421 [3]. Our observations support two conclusions. First, calcium-stim-
ulated microvesicle shedding depends on the level of membrane fluidity. This conclusion is
based on the strong two-dimensional correlation between microvesicle release and diphenylhex-
atriene fluorescence (Figure 5). The temperature dependence of microvesicle release observed
here (Figure 2) also corresponds well with other reports of erythrocyte physical behavior in the
range of 30 to 40°C [1,13,29,35-37]. The second conclusion is that the loss of membrane phos-
pholipid asymmetry that accompanies calcium loading is necessary for microvesicle release.
Effect of the scramblase inhibitor R5421 on ionomycin-stimulated microvesicle release Figure 6
Effect of the scramblase inhibitor R5421 on ionomycin-stimulated microvesicle release. Panel A: Phos-
phatidylserine migration to the outer leaflet of the cell membrane was assessed by fluorescence spectroscopy as 
described in Materials and Methods. Cells were treated with ionomycin in the presence or absence of 50 M 
R5421 (using DMSO as the control solvent for R5421). Panel B: The 37°C experiment of Figure 1A was repeated 
with erythrocyte samples incubated for 10 min without or with R5421 prior to addition of ionomycin or DMSO (as 
control solvent for ionomycin, labeled "Control"). In each case, the data represent the mean ± SEM (n = 13–19). 
The change in light scatter intensity from the initial minimum to that observed 240 s later (M) was calculated as in 
Figure 2.
       
         
                      
    
    
    
      
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
         
                 
 
   
   
   
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 PMC Biophysics 2009, 2:7 http://www.physmathcentral.com/1757-5036/2/7
Page 11 of 14
(page number not for citation purposes)
As always, one must exercise caution in interpreting data with MBCD. Although the com-
pound is used to manipulate membrane cholesterol content, it is also capable of extracting other
lipids [38]. For this reason, we use relatively mild extraction conditions (30 min incubation,  1
mM MBCD) [1,2]. Nevertheless, we cannot exclude the possibility that some of the observations
shown in Figures 4 and 5 involve lipids other than cholesterol. For this reason, our interpreta-
tions are based on relationships between the observed physical properties and membrane behav-
ior rather than trying to draw direct conclusions about cholesterol per se. We were able to
eliminate the possibility of non-specific direct artifacts of MBCD by including a control experi-
ment in which we pre-loaded the MBCD molecules with cholesterol (see Ref. [2] for experimental
details). Treatment of cells with pre-loaded MBCD had a significantly smaller effect on microves-
icle shedding compared to treatment with virgin MBCD (not shown).
An alternative explanation for the temperature effect in Figure 2 is that it reflects direct thermal
sensitivity of protein behavior independent of lipid properties. This possibility has been consid-
ered previously for the enzymes such as scramblase that mediate phosphatidylserine flip-flop
[13]. In that case, no temperature sensitivity was identified that could account for the data of Fig-
ure 2. Moreover, direct effects of temperature on protein activity or conformation alone cannot
explain the effects of MBCD shown in Figures 4 and 5. Finally, the data of Figure 3 exclude the
possibility that the temperature dependence was due to variation in the ability of ionomycin to
transport calcium.
How would the fluidity of the lipid bilayer affect the ability of the membrane to release vesi-
cles? This question is further complicated by an apparent paradox. On the one hand, microvesicle
release appears dependent on a membrane that is fluid and/or disordered at the time calcium is
introduced to the cell interior (Figures 4 and 5). On the other hand, influx of calcium causes the
membrane to become more ordered as the vesicles are shed [22]. Some evidence suggests that the
quandary may be resolved by considering the spatial distribution of physical properties along the
membrane surface. A study by Salzer et al. concluded that membrane liquid ordered domains
(termed "lipid rafts" in the paper) are involved in the vesiculation process because the microves-
icles are enriched in lipids and proteins typical of these domains [16]. Two-photon microscopy
of laurdan-labeled erythrocytes suggests that the increased membrane order associated with cal-
cium ionophore treatment is distributed unevenly across the membrane, perhaps representing an
expansion of liquid-ordered domains [1,3,13,22]. Therefore, as temperature is increased or cho-
lesterol is removed, the ordered domains propagated by ionophore treatment would be superim-
posed on a background of greater fluidity thus creating greater contrasts between these domains
and the surrounding lipids (as observed in Ref. [13]). Perhaps, then, enhanced microvesicle shed-
ding at high temperature or low cholesterol is explained by a more extreme diversity in lateral
bilayer structure. Whether the enhanced membrane fluidity promotes microvesicle release
directly or indirectly by altering the activity of membrane-bound enzymes cannot be distin-
guished by the experiments of this study.PMC Biophysics 2009, 2:7 http://www.physmathcentral.com/1757-5036/2/7
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The role of phosphatidylserine exposure in microvesicle release has been controversial. It is
well known that the two events are coincident when erythrocytes are loaded with calcium
[3,19,39]. Similar coincidence is also observed when erythrocytes are stimulated with lysophos-
phatidic acid [40]. Furthermore, blood cells from patients suffering from a bleeding disorder
known as Scott syndrome neither translocate phosphatidylserine across the cell membrane nor
release microvesicles in response to calcium ionophore [19].
Naturally, these observations of coincidence do not designate cause and effect. It is in the
attempts to establish causal relationships that the controversy has emerged. On the pro side,
microvesicle release in platelets appears to require translocation of phosphatidylserine [17]. A
similar claim has been made for erythrocytes [15]. One study used dithioerythritol to suppress
phospholipid scrambling and discovered that microvesicle release was likewise suppressed [20].
In contrast, in erythrocyte ghosts loaded with spermine, calcium induced microvesicle release
successfully even though phosphatidylserine translocation was severely reduced [21]. Similarly,
spermine-loaded ghosts from a Scott syndrome patient also released microvesicles in the com-
plete absence of phosphatidylserine flip-flop [21].
Inhibition of phosphatidylserine translocation with spermine or dithioerythritol is unlikely
to be specific. Hence, use of the specific scramblase inhibitor R5421 in the present study may
simplify interpretations. It also allowed experiments to be done on intact erythrocytes rather than
relying on ghosts, in which cytoskeletal and cytosolic components are altered or depleted. The
data shown in Figure 6 seem to provide an unambiguous interpretation with respect to cause and
effect. Therefore, phosphatidylserine translocation appeared to be required for microvesicle
release.
Conclusion
In summary, two conclusions are supported by the results of this study. First, calcium-stimulated
microvesicle release depends on the level of membrane fluidity. Second, loss of trans-membrane
phospholipid asymmetry is required for microvesicle shedding.
Physiologically, the results presented in this study may relate to the process of membrane
blebbing during apoptosis. It has been suggested that the microvesiculation of erythrocyte mem-
branes in response to calcium loading is a model for the blebbing that occurs as part of the apop-
totic process [41]. If this concept is true, it is logical to ask whether apoptotic membrane blebbing
requires increased membrane fluidity as described in this report for microvesicle release. The pos-
sibility has not yet been examined experimentally, but investigations demonstrating that apop-
totic cell membranes are more fluid or disordered than those of healthy cells support the viability
of the idea [42-47]. These bilayer changes occur early during apoptosis and could be the result of
phosphatidylserine exposure on the external membrane face [42,48-52] or other apoptotic
events [42]. Based on these observations and the data presented in this report, we propose thePMC Biophysics 2009, 2:7 http://www.physmathcentral.com/1757-5036/2/7
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hypothesis that increased fluidity of the cell membrane during apoptosis may be a necessary step
in preparation for cell membrane blebbing.
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